Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Moderna (NASDAQ: MRNA) has hit a bit of a snag with the manufacturing of its COVID-19 vaccine. The company’s fill-and-finish contractor, Catalent (NYSE: CTLT), is experiencing delays with some of the doses it’s responsible for getting out the door. The companies didn’t disclose eRead MoreMarketsMarkets Feed

¡Haz clic para votar esta entrada!
(Votos: 0 Promedio: 0)

Deja un comentario